Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT05703620

REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions.

Led by Royal Perth Hospital · Updated on 2023-01-30

75

Participants Needed

1

Research Sites

240 weeks

Total Duration

On this page

Sponsors

R

Royal Perth Hospital

Lead Sponsor

R

ReCor Medical, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The is a non-randomized pilot trial, open-label evaluation of the physiologic response of native kidney denervation using the Paradise denervation system in CKD, End Stage Renal Disease (ESRD), and Heart failure (HF)

CONDITIONS

Official Title

REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions.

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female patients
  • Age between 18 and 75 years
  • Able and willing to provide written informed consent
  • Diagnosis of either CKD stage 3a or 3b, or ESRD on stable renal replacement therapy, or mild to moderate heart failure with reduced ejection fraction
Not Eligible

You will not qualify if you...

  • Ineligible kidney anatomy for the procedure
  • Prior treatment with hypertension devices such as ROX Coupler, Mobius stent, or CVRx barostimulator
  • Heart attack, unstable angina, or stroke within 3 months before screening
  • Chronic active inflammatory bowel disease like Crohn's or ulcerative colitis
  • Significant heart valve disease unless corrected with a working prosthetic valve
  • Hospitalization for decompensated heart failure in the last month
  • Female of childbearing potential without a negative pregnancy test before treatment
  • History of drug or alcohol dependency, inability to follow instructions, or unlikely to comply with follow-up
  • Currently enrolled in another investigational drug or device trial
  • Disease or condition limiting life expectancy to less than 1 year (other than CKD, ESRD, or heart failure)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Royal Perth Hospital

Perth, Western Australia, Australia, 6000

Actively Recruiting

Loading map...

Research Team

A

Anu Joyson

CONTACT

M

Markus Schlaich

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here